Compare GNLX & HYPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNLX | HYPR |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.1M | 101.3M |
| IPO Year | 2022 | 2021 |
| Metric | GNLX | HYPR |
|---|---|---|
| Price | $2.68 | $0.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $17.25 | $1.59 |
| AVG Volume (30 Days) | 364.3K | ★ 542.2K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 9.47 | ★ 23.21 |
| EPS | N/A | ★ N/A |
| Revenue | $8,000.00 | ★ $13,563,000.00 |
| Revenue This Year | N/A | $50.75 |
| Revenue Next Year | N/A | $29.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 5.22 |
| 52 Week Low | $2.29 | $0.83 |
| 52 Week High | $8.54 | $2.22 |
| Indicator | GNLX | HYPR |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 32.62 |
| Support Level | $2.33 | N/A |
| Resistance Level | $2.98 | $1.19 |
| Average True Range (ATR) | 0.17 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 29.27 | 7.84 |
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales, which consist of sales from subscriptions of bundled devices, maintenance, and software. The company is in the health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. The Company operates in one business segment, which includes all activities related to production, supply, service, and commercialization of the Swoop system.